Elanco Animal Health - ELAN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $18.29
  • Forecasted Upside: 6.62%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$17.15
▲ +0.36 (2.14%)

This chart shows the closing price for ELAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elanco Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELAN

Analyst Price Target is $18.29
▲ +6.62% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $18.29, with a high forecast of $23.00 and a low forecast of $14.00. The average price target represents a 6.62% upside from the last price of $17.15.

This chart shows the closing price for ELAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Elanco Animal Health. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $19.00Low
5/9/2024BarclaysBoost TargetOverweight ➝ Overweight$19.00 ➝ $23.00Low
2/27/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$12.50 ➝ $14.00Low
2/27/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$16.00 ➝ $17.00Low
2/27/2024BarclaysBoost TargetOverweight ➝ Overweight$18.00 ➝ $19.00Low
1/17/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$10.00 ➝ $12.50Low
1/5/2024Stifel NicolausUpgradeHold ➝ Buy$13.00 ➝ $20.00Low
12/19/2023Jefferies Financial GroupInitiated CoverageBuy$17.00Low
12/15/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$16.00Low
12/7/2023Stifel NicolausBoost TargetHold ➝ Hold$12.00 ➝ $13.00Low
12/7/2023BNP ParibasInitiated CoverageOutperform$18.00Low
11/13/2023Piper SandlerBoost TargetNeutral ➝ Neutral$11.00 ➝ $12.00Low
11/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00Low
10/30/2023Stifel NicolausLower TargetHold ➝ Hold$13.00 ➝ $12.00Low
10/5/2023Piper SandlerLower Target$13.00 ➝ $11.00Low
8/14/2023Piper SandlerBoost TargetNeutral ➝ Neutral$9.00 ➝ $13.00Low
8/8/2023The Goldman Sachs GroupBoost TargetSell ➝ Sell$8.50 ➝ $9.50Low
4/20/2023BarclaysUpgradeEqual Weight ➝ Overweight$14.00Low
3/2/2023Piper SandlerLower Target$15.00 ➝ $12.00Low
2/22/2023BarclaysLower TargetEqual Weight$18.00 ➝ $14.00Low
1/30/2023Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00Low
11/15/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00Low
11/14/2022Piper SandlerLower TargetNeutral$21.00 ➝ $15.00Low
11/9/2022The Goldman Sachs GroupLower TargetSell$19.00 ➝ $12.00Low
11/8/2022William BlairReiterated RatingMarket PerformLow
10/17/2022JPMorgan Chase & Co.Lower TargetNeutral$24.00 ➝ $20.00Low
10/7/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $21.00Low
9/12/2022BarclaysLower TargetEqual Weight$32.00 ➝ $18.00Low
8/18/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$37.00 ➝ $22.00Low
8/16/2022Piper SandlerLower TargetNeutral$22.00 ➝ $21.00Low
8/16/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $24.00Low
7/21/2022The Goldman Sachs GroupDowngradeBuy ➝ Sell$32.00 ➝ $19.00Low
7/11/2022Piper SandlerInitiated CoverageNeutral$22.00N/A
6/24/2022Stifel NicolausLower TargetHold$30.00 ➝ $22.00Low
5/19/2022The Goldman Sachs GroupLower TargetBuy$37.00 ➝ $32.00Low
5/17/2022Morgan StanleyLower TargetOverweight$37.00Low
2/28/2022BarclaysBoost TargetEqual Weight$30.00 ➝ $32.00Low
12/8/2021BarclaysReiterated RatingNeutral ➝ HoldHigh
11/18/2021Morgan StanleyInitiated CoverageOverweight$40.00Medium
10/28/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $34.00Medium
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$38.00High
5/17/2021CitigroupReiterated RatingBuy$39.00 ➝ $42.00High
5/11/2021G.ResearchUpgradeHold ➝ BuyLow
5/11/2021GabelliUpgradeHold ➝ BuyMedium
5/11/2021BarclaysUpgradeUnderweight ➝ Equal Weight$25.00 ➝ $29.00Medium
4/20/2021Stifel NicolausInitiated CoverageBuy$37.00N/A
4/14/2021Stifel NicolausInitiated CoverageBuy$37.00Low
3/29/2021GabelliReiterated RatingBuy ➝ Hold$32.00High
3/22/2021GabelliDowngradeBuy ➝ Hold$32.00High
3/22/2021Raymond JamesReiterated RatingHoldHigh
3/8/2021CitigroupBoost Target$35.00 ➝ $39.00Low
2/26/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$33.00 ➝ $38.00High
12/9/2020ArgusDowngradeBuy ➝ HoldMedium
11/23/2020Morgan StanleyBoost TargetOverweight$31.00 ➝ $41.00High
11/9/2020BarclaysDowngradeOverweight ➝ Underweight$35.00 ➝ $25.00High
10/26/2020BarclaysBoost TargetOverweight$25.00 ➝ $35.00Medium
10/7/2020Raymond JamesReiterated RatingHoldMedium
10/1/2020CitigroupBoost TargetBuy$27.00 ➝ $32.00Medium
9/28/2020Raymond JamesReiterated RatingHoldLow
8/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$24.00 ➝ $31.00High
8/18/2020ArgusBoost TargetPositive ➝ Buy$26.00 ➝ $30.00Low
8/12/2020Credit Suisse GroupInitiated CoverageNeutral$27.00Medium
8/4/2020The Goldman Sachs GroupInitiated CoverageBuy$26.50High
7/20/2020Bank of AmericaBoost TargetBuy$26.00 ➝ $28.00Low
5/15/2020CitigroupLower TargetBuy$35.00 ➝ $27.00Medium
5/13/2020BarclaysReiterated RatingBuy$25.00Medium
4/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
3/25/2020Credit Suisse GroupReiterated RatingBuyHigh
1/14/2020GabelliReiterated RatingBuyHigh
1/9/2020Raymond JamesInitiated CoverageMarket PerformHigh
12/19/2019Bank of AmericaUpgradeNeutral ➝ Buy$34.00High
11/20/2019UBS GroupLower TargetNeutral$30.00 ➝ $28.00Low
11/7/2019Morgan StanleyUpgradeEqual ➝ Equal Weight$34.00 ➝ $32.00Medium
9/23/2019BarclaysInitiated CoverageOverweight$36.00Medium
9/9/2019The Goldman Sachs GroupInitiated CoveragePositiveMedium
8/26/2019Bank of AmericaDowngradeBuy ➝ Neutral$30.00Low
8/15/2019UBS GroupUpgradeSell ➝ Neutral$31.00 ➝ $30.00Medium
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/31/2023
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2023
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 14 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/29/2024
  • 19 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
2/28/2024
  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/28/2024
  • 20 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 20 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Elanco Animal Health logo
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Read More

Today's Range

Now: $17.15
Low: $16.77
High: $17.18

50 Day Range

MA: $15.25
Low: $12.93
High: $17.21

52 Week Range

Now: $17.15
Low: $7.88
High: $17.43

Volume

5,372,042 shs

Average Volume

4,508,870 shs

Market Capitalization

$8.48 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Elanco Animal Health?

The following sell-side analysts have issued research reports on Elanco Animal Health in the last twelve months: Barclays PLC, BNP Paribas, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for ELAN.

What is the current price target for Elanco Animal Health?

7 Wall Street analysts have set twelve-month price targets for Elanco Animal Health in the last year. Their average twelve-month price target is $18.29, suggesting a possible upside of 6.6%. Barclays PLC has the highest price target set, predicting ELAN will reach $23.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $14.00 for Elanco Animal Health in the next year.
View the latest price targets for ELAN.

What is the current consensus analyst rating for Elanco Animal Health?

Elanco Animal Health currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ELAN.

What other companies compete with Elanco Animal Health?

How do I contact Elanco Animal Health's investor relations team?

Elanco Animal Health's physical mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company's listed phone number is (877) 352-6261 and its investor relations email address is [email protected]. The official website for Elanco Animal Health is www.elanco.com. Learn More about contacing Elanco Animal Health investor relations.